

## Clover Biopharmaceuticals, Ltd. 三葉草生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2197)

## FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING

ess)			
e holder(	(s) of(see	Note 1) shares of US\$0.00	01 each in the capital of
Biopharm	aceuticals, Ltd. (the "Company") hereby appoint (Name)		of
s)			or
im/her, that B5-19, 2025 at	ne chairman of the meeting <sup>(see Note 2)</sup> as my/our proxy to attend and vote for me/us and on my/our bel Building 1, High-tech Incubation Park, No. 1480, Tianfu Avenue (North), Chengdu High-Tech Zone, 10:00 a.m. (the "Meeting"), and at any adjournment thereof or on any resolution or motion which	half at the annual general m China (Sichuan) Pilot Free	eeting of the Company to Trade Zone on Thursday,
	Ordinary Resolutions (see Note 3)	For (see Note 3)	Against (see Note 3)
To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended December 31, 2024.			
To re-e	lect the following persons:		
(a)	Dr. Donna Marie AMBROSINO, non-executive director		
(b)	Mr. Thomas LEGGETT, independent non-executive director		
To auth	orise the board of directors of the Company to fix the remuneration of the directors.		
next an	t annual general meeting of the Company and to authorise the board of directors of the Company to fix its		
(A)			
(B)			
(C)			
Di	-		
A shareho	older may appoint more than one proxy of his/her own choice. If such an appointment is made, strike out the words "the chairman		
MARKE other than	D "Against". Failure to tick a box will entitle your proxy to cast your vote at his/her discretion. Your proxy will also be entitled to ven those referred to in the notice convening the Meeting.	ote at his/her discretion on any reso	
		•	
In the case of joint holders, the signature of any one holder will be sufficient but the names of all the joint holders should be stated. Where there are joint holders of any share of the Company, any one of such joint holders may vote at the Meeting, either in person or by proxy, in respect of such share as if he/she were solely entitled thereto, but if more than one of such joint holders be present at the Meeting, the vote of the senior who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint holders, and for this purpose seniority shall be determined as that one of the said persons so present whose name stands first on the register of members of the Company in respect of such share shall alone be entitled to vote in respect thereof.			
To be valid, this form of proxy must be completed, signed and deposited at the Hong Kong branch share registrar and transfer office of the Company, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, together with the power of attorney or other authority (if any) under which it is signed (or a notarially certified copy thereof), not less than 48 hours before the time for holding the Meeting (i.e. before 10:00 a.m. on June 17, 2025). The completion and return of the form of proxy shall not preclude shareholders of the Company from attending and voting in person at the above Meeting (or any adjourned meeting thereof) if they so wish.			
	A proxy need not be a shareholder of the Company.  The full text of the resolutions is set out in the notice of the Meeting dated May 21, 2025.		
inc tull t	PERSONAL INFORMATION COLLECTION STATEMENT		
	re holders be him/her, that B5-19, 2025 at ed to vote be do not be holders be	Biopharmaceuticals, Ltd. (the "Company") hereby appoint (Name)  s)  im/her, the chairman of the meeting (**e** Note* 2)* as my/our proxy to attend and vote for me/us and on my/our belat B5-19, Building 1, High-tech Incubation Park, No. 1480, Tianfu Avenue (North), Chengdu High-Tech Zone, 2025 at 10:00 a.m. (the "Meeting"), and at any adjournment thereof or on any resolution or motion which is dot vote as indicated (**e** Note* 3)* in respect of the undermentioned resolutions:  **Ordinary Resolutions** (**e** Note* 3)**  To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended December 31, 2024.  To re-elect the following persons:  (a)  Dr. Donna Marie AMBROSINO, non-executive director  To authorise the board of directors of the Company to fix the remuneration of the directors.  To appoint CL Partners CPA Limited as the auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorise the board of directors of the Company to fix its remuneration.  (A)  To give a general mandate to the directors of the Company to allot, issue and deal with additional shares and/or sell or transfer treasury shares (if any) not exceeding 20% of the issued share capital of the Company (excluding treasury shares, if any) as at the date of this resolution.  (B)  To give a general mandate to the directors of the Company pursuant to ordinary resolution no. 5(A) to issue share capital of the Company (excluding treasury shares, if any) as at the date of this resolution.  (C)  To extend the authority given to the directors of the Company pursuant to ordinary resolution no. 5(A) to issue shares and/or sell or transfer treasury shares (if any) by adding to the issued share capital of the Company the number of shares repurchased under ordinary resolution no. 5(A) to issue shares and/or sell or transfer treasury shares (if any) by adding to the issued share capital of the Comp	the holder(s) of

"Personal Data" in this form of proxy has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Cap 486 ("PDPO"), which includes your and your proxy's name and address.

You and your proxy's Personal Data provided in this form of proxy will be used in connection with processing your request for the appointment of a proxy to attend, act and vote on your behalf as directed above at the Meeting. The supply of your and your proxy's Personal Data is on a voluntary basis. However, the Company may not be able to process your request unless you provide us with your and your proxy's Personal Data.

Your and your proxy's Personal Data will be disclosed or transferred to the Company's share registrar and its Hong Kong branch share registrar and transfer office and/or other companies or bodies for the purpose stated above, or when it is required to do so by law, for example, in response to a court order or a law enforcement agency's request, and will be retained for such period as may be necessary for our verification and record purpose.

By providing your proxy's Personal Data in this form of proxy, you should have obtained the express consent (which has not been withdrawn in writing) from your proxy in using his/her Personal Data provided in this form of proxy and that you have informed your proxy of the purpose for and the manner in which his/her Personal Data may be used.

You/your proxy have/has the right to request access to and/or correction of your/your proxy's Personal Data respectively in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your/your proxy's Personal Data should be in writing by either of the following means

By mail to: Hong Kong Privacy Officer
Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong
By email to: PrivacyOfficer@computershare.com.hk

I/We (Name) (Block Capital, please)